Screener
G&A at other companies
Other financials
Where this comes from
Reported directly by Enliven Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.
The source filing: Enliven Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:17 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-211982
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Operating expenses: | ||
| Research and development | $20,687 | $24,895 |
| General and administrative | 7,136 | 6,798 |
| Total operating expenses | 27,823 | 31,693 |
| Loss from operations | (27,823) | (31,693) |
| Other income (expense), net | ||
| Interest income | 4,196 | 3,196 |
| Other expense | — | (47) |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Enliven Therapeutics's G&A?
- Enliven Therapeutics (ELVN) reported G&A of $7.14M in Q1 2026.
- How has Enliven Therapeutics's G&A changed year-over-year?
- Enliven Therapeutics's G&A increased by 5.0% year-over-year, from $6.8M to $7.14M.
- What is the long-term trend for Enliven Therapeutics's G&A?
- Over 4 years (2021 to 2025), Enliven Therapeutics's G&A has grown at a 27.0% compound annual growth rate (CAGR), from $13M to $33.8M.
- What does G&A mean?
- Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.
Ask your AI about Enliven Therapeutics's g&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude